Alkermes Pharma Ireland Limited

Pfizer Corporation

Pfizer Products Inc.

Alkermes, Inc.

Other

Laura Cook Blumberg

Tarek A Zeidan

Julius F Remenar

Orn Almarsson

David J Eyerman

Michael John Munchhof

Daniel R Deaver

Thomas Andrew Wynn

Örn Almarsson

John Adams Lowe, Iii

Juan C Alvarez

Derrick Arnelle

Matthew Frank Brown

Andrei Shavnya

Christopher Stanley Poss

Matthew Merrill Hayward

Ronald P Gladue

Andre Shavnya

Gregory D Lundquist

Molly A McGlynn

Dan Deaver

Juan Alvarez

John Adam Lowe

Gregory Dean Lundquist

Orn Almarrson

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

Methods for treating depressive symptoms

Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

Heterocyclic compounds for the treatment of neurological and psychological disorders

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a &#x3bc; opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. 

The present invention relates to compounds of Formula I: 

Prodrugs of secondary amine compounds

The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.

Morphan and morphinan analogues, and methods of use

The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

Prodrugs of Nh-acidic compounds

The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.

Multi-API loading prodrugs

Prodrugs of NH-acidic compounds

The present application relates to analogs of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.

Growing community of inventors

Lincoln, MA, United States of America

Laura Cook Blumberg